What is the Oncotype DX® test, and what makes it unique?
The Oncotype DX Breast Recurrence Score test has been developed for patients with early-stage HR+, HER2- breast cancer to:
- Identify those patients who may benefit from chemotherapy1,2
- Determine the magnitude of chemotherapy benefit1-5
- Support treatment decisions1-5
Chemotherapy can cause both short- and long-term side effects affecting current and future health, quality of life, family life and work life.6-8 The vast majority of patients with HR+, HER2- early-stage breast cancer do not benefit from adjuvant chemotherapy.9
Oncotype DX test: predicts chemotherapy benefit and disease outcome
The Oncotype DX test is the only
Prediction of chemotherapy benefit based on prospective clinical trials makes the Oncotype DX test unique
Development of the Oncotype DX test
The Oncotype DX test was developed to assess disease prognosis and predict benefit from chemotherapy (CT) in patients with early-stage, HR+, HER2- breast cancer.
The Oncotype DX test was developed to predict chemotherapy benefit based on a unique understanding of tumour biology.
The Oncotype DX test reveals individual tumour biology based on measuring the expression of 21 genes1, 11
What information does the Oncotype DX test provide?
The Oncotype DX test identifies patients who may benefit from adjuvant chemotherapy, or not, by providing three pieces of information: the Recurrence Score result, the risk of distant recurrence, and the estimated chemotherapy benefit.
Learn more about the Oncotype DX test for:
Guiding treatment with the Oncotype DX test
In summary, thanks to the comprehensive clinical evidence for both node-negative and node-positive patients, the Oncotype DX test can help guide confident chemotherapy treatment decisions.
Abbreviations
References
